Skip to main content
Top
Published in: Tumor Biology 12/2016

01-12-2016 | Original Article

Prognostic risk factors in patients with bone metastasis from colorectal cancer

Authors: Fangqi Liu, Jiang Zhao, Jie Xie, Li Xie, Ji Zhu, Sanjun Cai, Hongtu Zheng, Ye Xu

Published in: Tumor Biology | Issue 12/2016

Login to get access

Abstract

The morbidity of bone metastasis (BM) from colorectal cancer (CRC) is increasing more than ever; however, insufficient research on BM from CRC leads to reduced awareness of the issue. Therefore, the aim of this study was to evaluate the clinical features and prognostic risk factors of CRC patients with BM. Clinical data were retrospectively analyzed for a total of 242 CRC patients with BM. Of the 242 CRC patients with BM, 52 (21.5 %) had bone metastasis alone (BMA) and 190 (78.5 %) had both bone and visceral metastasis (BM&VM). The median survival time (MST) after the diagnosis of BM in all 242 patients was 15.6 months (95 % confidence interval [CI] 12.74–18.46 months). The MST of the BMA group was significantly longer than that of the BM&VM group (29.1 vs. 12.8 months, p = 0.003). Using a Cox proportional hazard model, we identified a high carcinoembryonic antigen (CEA) level and BMA as independent prognostic factors for CRC patients with BM. For the BMA group, the independent prognostic factors were elevated alkaline phosphatase (ALP) and perineural invasion of the primary cancer, which were distinct from the factors for the entire group of BM patients. Furthermore, we found that the BMA patients with multiple sites of BM had similar prognosis to the BM&VM patients. These findings together provide us with a further understanding of BM from CRC and reveal that BMA may be a distinct subset of BM from CRC that has unique independent prognostic factors and a good prognosis.
Literature
1.
go back to reference Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563–72.CrossRefPubMed Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563–72.CrossRefPubMed
2.
go back to reference Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon rectum. 1999;42(12):1592–7. Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon rectum. 1999;42(12):1592–7.
3.
go back to reference Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of oncology: official journal of the European Society for Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of oncology: official journal of the European Society for
4.
go back to reference Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005;5(2):108–13.CrossRefPubMed Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005;5(2):108–13.CrossRefPubMed
5.
go back to reference Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(31):4697–705.CrossRef Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(31):4697–705.CrossRef
6.
go back to reference Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of clinical oncology: official journal of the. Proc Am Soc Clin Oncol. 2008;26(12):2013–9.CrossRef Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of clinical oncology: official journal of the. Proc Am Soc Clin Oncol. 2008;26(12):2013–9.CrossRef
7.
go back to reference Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.CrossRefPubMed Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.CrossRefPubMed
8.
go back to reference Besbeas S, Stearns MW. Osseous metastases from carcinomas of the colon and rectum. Dis Colon rectum. 1978;21(4):266–8. Besbeas S, Stearns MW. Osseous metastases from carcinomas of the colon and rectum. Dis Colon rectum. 1978;21(4):266–8.
9.
go back to reference Nozue M, Oshiro Y, Kurata M, Seino K-I, Koike N, Kawamoto T, et al. Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep. 2002;9(1):109–12.PubMed Nozue M, Oshiro Y, Kurata M, Seino K-I, Koike N, Kawamoto T, et al. Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep. 2002;9(1):109–12.PubMed
10.
go back to reference Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S, et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiol. 2014;38(4):427–34.CrossRefPubMed Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S, et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiol. 2014;38(4):427–34.CrossRefPubMed
11.
go back to reference Qiu M, Hu J, Yang D, Cosgrove DP, Xu R. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget. 2015;6(36):38658–66.PubMedPubMedCentral Qiu M, Hu J, Yang D, Cosgrove DP, Xu R. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget. 2015;6(36):38658–66.PubMedPubMedCentral
12.
13.
go back to reference Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15(12):3433–9.CrossRefPubMed Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15(12):3433–9.CrossRefPubMed
14.
go back to reference Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon rectum. 1994;37(3):272–7. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon rectum. 1994;37(3):272–7.
15.
go back to reference Rama N, Monteiro A, Bernardo JE, Eugénio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2009;35(3):444–9.CrossRef Rama N, Monteiro A, Bernardo JE, Eugénio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2009;35(3):444–9.CrossRef
16.
go back to reference Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg. 1998;66(1):214–8 - discussion 8-9.CrossRefPubMed Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg. 1998;66(1):214–8 - discussion 8-9.CrossRefPubMed
17.
go back to reference Farley JR, Baylink DJ. Skeletal alkaline phosphatase activity as a bone formation index in vitro. Metab Clin Exp. 1986;35(6):563–71.CrossRefPubMed Farley JR, Baylink DJ. Skeletal alkaline phosphatase activity as a bone formation index in vitro. Metab Clin Exp. 1986;35(6):563–71.CrossRefPubMed
18.
go back to reference Mountzios G, Ramfidis V, Terpos E, Syrigos KN. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clinical lung cancer. 2011;12(6):341–9.CrossRefPubMed Mountzios G, Ramfidis V, Terpos E, Syrigos KN. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clinical lung cancer. 2011;12(6):341–9.CrossRefPubMed
19.
go back to reference Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115(15):3379–91.CrossRefPubMed Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115(15):3379–91.CrossRefPubMed
20.
go back to reference Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, et al. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Oncology. 2011;81(3–4):175–83.CrossRefPubMed Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, et al. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Oncology. 2011;81(3–4):175–83.CrossRefPubMed
21.
go back to reference Delva R, Pein F, Lortholary A, Gamelin E, Cellier P, Larra F. [bone metastases of colorectal cancers: apropos of 8 cases]. La Revue de Médecine Interne. 1993;14(4):223–8.CrossRefPubMed Delva R, Pein F, Lortholary A, Gamelin E, Cellier P, Larra F. [bone metastases of colorectal cancers: apropos of 8 cases]. La Revue de Médecine Interne. 1993;14(4):223–8.CrossRefPubMed
Metadata
Title
Prognostic risk factors in patients with bone metastasis from colorectal cancer
Authors
Fangqi Liu
Jiang Zhao
Jie Xie
Li Xie
Ji Zhu
Sanjun Cai
Hongtu Zheng
Ye Xu
Publication date
01-12-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5465-4

Other articles of this Issue 12/2016

Tumor Biology 12/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine